Cargando…
A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis
PURPOSE: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. SUBJECTS AND METHODS: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characte...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432897/ https://www.ncbi.nlm.nih.gov/pubmed/30962701 http://dx.doi.org/10.2147/CCID.S179430 |
_version_ | 1783406219995643904 |
---|---|
author | Gfeller, Christoph F Wanser, Rita Mahalingam, Harish Moore, David J Wang, Xuying Lin, Connie B Shanga, Gilbert Grove, Gary Rawlings, Anthony V |
author_facet | Gfeller, Christoph F Wanser, Rita Mahalingam, Harish Moore, David J Wang, Xuying Lin, Connie B Shanga, Gilbert Grove, Gary Rawlings, Anthony V |
author_sort | Gfeller, Christoph F |
collection | PubMed |
description | PURPOSE: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. SUBJECTS AND METHODS: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characterization of normal vs dry lips, and a randomized, evaluator-blinded, clinical trial that assessed the lip cream in healthy subjects with dry lips were conducted. In the clinical trial, subjects applied the lip cream or were untreated and evaluated using transepidermal water loss (TEWL), corneometry, visual assessments of lip dryness, expert photographic evaluations, and subject-rated outcomes. RESULTS: The lip cream’s in vitro water vapor transmission rate (84.1 g/(m(2) h)) indicated moderate occlusivity. The lip cream, but not placebo or control (water), reduced ultraviolet A (UVA)- and UVB-induced DNA damage, and tumor necrosis factor-α (EpiDerm(FT)) and pros-taglandin E(2) release (EpiDerm(FT) and EpiGingival™). The lip cream’s in vivo sun protection factor (SPF) was 12.2 (lower confidence limit, 11.3) and SPF/UVA protection factor ratio was 0.9. The characterization of dry vs normal lips identified differences in moisturization. In the clinical trial, the lip cream significantly decreased TEWL (difference: −7.19 [95% CI: −11.41, −2.98]; P<0.01), increased corneometry (difference: 4.62 [95% CI: 1.05, 8.19]; P<0.05), and reduced visual dryness (difference: −1.48 [95% CI: 2.24, −0.71]; P<0.001) compared to untreated subjects. Significant benefits were also observed on expert photographic assessments of scaling (difference: −0.89 [95% CI: −1.75, −0.03]; P< 0.05), cupping (difference: −1.50 [95% CI: −2.30, −0.70]; P<0.001), and healthy appearance (difference: −1.44 [95% CI: −2.29, −0.58]; P<0.01); differences in overall healthy appearance were not significant (P=0.51). Subject-rated assessments indicated improvements in cracking, dryness, and flaking in the lip cream group but worsening in untreated subjects. CONCLUSION: These studies indicate that this novel, daily-use lip cream protects against UV radiation, drying, and chapping, which are established environmental RHL triggers. |
format | Online Article Text |
id | pubmed-6432897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64328972019-04-08 A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis Gfeller, Christoph F Wanser, Rita Mahalingam, Harish Moore, David J Wang, Xuying Lin, Connie B Shanga, Gilbert Grove, Gary Rawlings, Anthony V Clin Cosmet Investig Dermatol Original Research PURPOSE: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. SUBJECTS AND METHODS: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characterization of normal vs dry lips, and a randomized, evaluator-blinded, clinical trial that assessed the lip cream in healthy subjects with dry lips were conducted. In the clinical trial, subjects applied the lip cream or were untreated and evaluated using transepidermal water loss (TEWL), corneometry, visual assessments of lip dryness, expert photographic evaluations, and subject-rated outcomes. RESULTS: The lip cream’s in vitro water vapor transmission rate (84.1 g/(m(2) h)) indicated moderate occlusivity. The lip cream, but not placebo or control (water), reduced ultraviolet A (UVA)- and UVB-induced DNA damage, and tumor necrosis factor-α (EpiDerm(FT)) and pros-taglandin E(2) release (EpiDerm(FT) and EpiGingival™). The lip cream’s in vivo sun protection factor (SPF) was 12.2 (lower confidence limit, 11.3) and SPF/UVA protection factor ratio was 0.9. The characterization of dry vs normal lips identified differences in moisturization. In the clinical trial, the lip cream significantly decreased TEWL (difference: −7.19 [95% CI: −11.41, −2.98]; P<0.01), increased corneometry (difference: 4.62 [95% CI: 1.05, 8.19]; P<0.05), and reduced visual dryness (difference: −1.48 [95% CI: 2.24, −0.71]; P<0.001) compared to untreated subjects. Significant benefits were also observed on expert photographic assessments of scaling (difference: −0.89 [95% CI: −1.75, −0.03]; P< 0.05), cupping (difference: −1.50 [95% CI: −2.30, −0.70]; P<0.001), and healthy appearance (difference: −1.44 [95% CI: −2.29, −0.58]; P<0.01); differences in overall healthy appearance were not significant (P=0.51). Subject-rated assessments indicated improvements in cracking, dryness, and flaking in the lip cream group but worsening in untreated subjects. CONCLUSION: These studies indicate that this novel, daily-use lip cream protects against UV radiation, drying, and chapping, which are established environmental RHL triggers. Dove Medical Press 2019-03-22 /pmc/articles/PMC6432897/ /pubmed/30962701 http://dx.doi.org/10.2147/CCID.S179430 Text en © 2019 Gfeller et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Gfeller, Christoph F Wanser, Rita Mahalingam, Harish Moore, David J Wang, Xuying Lin, Connie B Shanga, Gilbert Grove, Gary Rawlings, Anthony V A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title | A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title_full | A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title_fullStr | A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title_full_unstemmed | A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title_short | A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
title_sort | series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432897/ https://www.ncbi.nlm.nih.gov/pubmed/30962701 http://dx.doi.org/10.2147/CCID.S179430 |
work_keys_str_mv | AT gfellerchristophf aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT wanserrita aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT mahalingamharish aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT mooredavidj aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT wangxuying aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT linconnieb aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT shangagilbert aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT grovegary aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT rawlingsanthonyv aseriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT gfellerchristophf seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT wanserrita seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT mahalingamharish seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT mooredavidj seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT wangxuying seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT linconnieb seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT shangagilbert seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT grovegary seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis AT rawlingsanthonyv seriesofinvitroandhumanstudiesofanovellipcreamformulationforprotectingagainstenvironmentaltriggersofrecurrentherpeslabialis |